References
- O. Andreas, Process validation of oral solid dosage forms: A semiscientific overview, Pharm. Technol. Eur., 9, 30-38 (1997)
- FDA, Center for Drug Evaluation and Research, Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, August 2000
- FDA, Center for Drug Evaluation and Research, Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug products General considerations, October 2000
- FDA, Center for Drug Evaluation and Research, Guidance for Industry: SUPAC-IR: Immediate release solid oral dosage forms: Scale-up and postapproval changes: Chemistry, manufacturing and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, November 1995
- FDA, Center for Drug Evaluation and Research, Guidance for Industry: SUPAC-MR: Modified release solid oral dosage forms: Scale-up and postapproval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing and in vivo bioequivalence documentation, September 1997
- 식품의약품안전청고시 의약품동등성시험관리규정 제2002-19호, 2002년 4월
- 일본국립의약품식품위생연구소 (National Institute of Health Sciences), Guideline for bioequivalence studies of generic products, December 1997
- S. Dawoodbhai, et al., Optimization of tablet formulation containing talc, Drug Dev. Ind. Pharm., 17, 1343-1371 (1991) https://doi.org/10.3109/03639049109057301
- F. Langenbucher, Linerization of dissolution rate curves by the Weibull distribution, J. Pharm. Pharmacol., 24, 979-981 (1972) https://doi.org/10.1111/j.2042-7158.1972.tb08930.x
- L. Kervinen and J. Yiruusi, Modelling S-Shaped dissolution curves, Int. J. Pharm. 92, 115-122 (1993) https://doi.org/10.1016/0378-5173(93)90270-P
- P. Costa and J.M.S. Lobo, Influence of dissolution medium agitation on release profiles of sustained-release tablets, Drug Dev. Ind. Pharm., 27, 811-817 (2001) https://doi.org/10.1081/DDC-100107244
- J.W. Moore and H.H. Flanner, Mathematical comparison of dissolution profiles, Pharm. Tech. 20, 64-74 (1996)
- 일본국립의약품식품위생연구소 (National Institute of Health Sciences), Guideline for bioequivalence studies for formulation changes of oral solid dosage forms, February 2000
- 일본국립의약품식품위생연구소 (National Institute of Health Sciences), Guideline for bioequivalence studies for different strengths of oral solid dosage forms, February 2000
-
J.P. Liu, M.C. Ma and S.C. Chow, Statistical evaluation of similarity factor
$\f_{2}$ as a criterion for assessment of similarity between dissolution profiles, Drug Info. J., 31, 1255-1271 (1997) https://doi.org/10.1177/009286159703100426 -
V.P. Shah, Y. Tsong, P. Sathe and J.P. Liu, In vitro dissolution profile comparison: Statistics and analysis of the similarity factor,
$\f_{2}$ , Pharm. Res., 15, 889-896 (1998) https://doi.org/10.1023/A:1011976615750 - H.L. Ju and S.J. Liaw, On the assessment of similarity of drug dissolution profiles: A simulation study, Drug Info. J., 31, 1273-1289 (1997) https://doi.org/10.1177/009286159703100427
- A. Rescigno, Bioequivalence, Pharm. Res., 9, 925-928 (1992) https://doi.org/10.1023/A:1015809201503
- M. C. Gohel and M.K. Panchal, Comparison of in vitro dissolution profiles using a novel, model-independent approach, Pharm. Tech., 24, 92-102 (2000)
- FDA, Center for Drug Evaluation and Research, Guidance for Industry: Dissolution testing of immediate release solid oral dosage forms, August 1997
- EMEA, Note for guidance on quality of modified release products: A: Oral dosage forms B: Transdermal dosage forms, Section 1 (Quality), January 2000
Cited by
- Formulation optimization and pharmacokinetics evaluation of oral self-microemulsifying drug delivery system for poorly water soluble drug cinacalcet and no food effect vol.44, pp.6, 2018, https://doi.org/10.1080/03639045.2018.1425428